drugset / Trial / NCT06693128
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a multicenter, randomized, uncontrolled clinical trial to evaluate the efficacy and safety of camrelizumab combined with or without apatinib and SOX of neoadjuvant treatment for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.
Timeline
- Start
- 2024-11-21
- Primary completion
- 2026-05-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Rivoceranib | Small molecule | 250 mg | — |
| Background | Oxaliplatin | Small molecule | — | — |
| Background | S-1 | Small molecule | — | — |